Advarra

JANUARY 11, 2024

After injection of such a vaccine, the mRNA instructs cells to produce proteins designed to stimulate an immune response against these same protein targets when they show up in viruses or in tumor cells. Adoptive T Cell Therapies Adoptive T cell therapy is another form of cancer treatment leveraging the patient’s immune system.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

DrugBank

FEBRUARY 26, 2025

Advances in genetic engineering have enabled researchers to enhance bacteriophage efficacy and overcome bacterial resistance mechanisms. Developing Antimicrobial Peptides and Biomolecules In addition to traditional small-molecule antibiotics, researchers are exploring the potential of antimicrobial peptides (AMPs) and other biomolecules.

Therapies 52

Therapies Pharmaceutical Companies Pharmacokinetics Treatment 52

Codon

APRIL 30, 2023

Read more at Nature Biotechnology ( Similar paper at Nature Biomedical Engineering.) But now, their engineered brethren can live about 82 percent longer. Often, when we engineer a cell, we only mess with the magnitude of an effect; this study suggests that we should think more about the timing, too. From Zhang et al.

Vaccine 52

Vaccine DNA Engineering RNA 52

Codon

APRIL 30, 2023

Read more at Nature Biotechnology ( Similar paper at Nature Biomedical Engineering.) But now, their engineered brethren can live about 82 percent longer. Often, when we engineer a cell, we only mess with the magnitude of an effect; this study suggests that we should think more about the timing, too. From Zhang et al.

Vaccine 52

Vaccine DNA Engineering RNA 52

The Pharma Data

JANUARY 17, 2021

Johnson & Johnson published interim Phase I/IIa data in the New England Journal of Medicine showing its single-dose COVID-19 vaccine candidate created an immune response that lasted at least 71 days. The data showed that the vaccine induced an immune response and was generally well-tolerated. Most Read Today.

Immune Response 52

Immune Response Small Molecule Clinical Trials Trials 52

DrugBank

FEBRUARY 5, 2025

Nanoparticles, ranging from 1 to 100 nanometers, can be engineered with surface modifications that enable them to recognize and bind to specific biomarkers or receptors overexpressed on the surface of target cells. These ligands can be antibodies, peptides, aptamers, or small molecules.

Drugs 52

Drugs Engineering Vaccine Treatment 52

The Pharma Data

AUGUST 3, 2021

whose proprietary peptide- and protein-engineering platform is used to identify and synthesize molecules that can sense glucose or other endogenous modulators of protein activity. The company announced the acquisition of Protomer Technologies Inc., Loxo Oncology at Lilly and Kumquat Biosciences Inc.

Production 52

Production Marketing Research Government 52

The Pharma Data

SEPTEMBER 15, 2020

With the depth and breadth of our current portfolio, the tremendous potential of our pipeline and scientific engine, and the power of our culture of innovation, we are poised to continue delivering meaningful value to patients by addressing some of the world’s most difficult health challenges.”. mg/dL reduction for placebo.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

Drug Target Review

DECEMBER 13, 2024

Engineering sites on the antibody to enable specific and consistent attachment of the cytotoxic drug to achieve an optimal drug-to-antibody ratio (DAR). The development of more hydrophilic linkers helps maintain the structural and functional integrity of the antibody in the final conjugate.

Therapies 98

Therapies Treatment Clinical Trials Drugs 98

The Pharma Data

DECEMBER 27, 2020

It is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory diseases. platform and its large-capacity VV Cop TK”RR” oncolytic virus, engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody generated by BioInvent’s n-CoDeR/F.I.R.S.T.

Clinical Trials 52

Clinical Trials Trials Therapies Virus 52

Codon

APRIL 16, 2023

Codon Digest is my weekly roundup of research, news, and industry highlights about engineered biology. Skin microbes can trigger strong immune responses. In other words: Brush some engineered bacteria on the skin, and they activate the immune system to go fight a tumor. Metabolic Engineering. Wichmann J.

Engineering 52

Engineering DNA RNA Science 52

Codon

DECEMBER 12, 2024

It’s difficult to imagine any evolutionary path that could “reverse” the tangled molecules of life into their mirrored forms, because incremental mutations which swap out a few chiral molecules for their enantiomers would impair or kill the cell. The report maps out at least three options.

RNA 104

RNA DNA Vaccine Virus 104

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 8, 2020

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

Codon

MARCH 26, 2023

Link Biological Engineering *Photosynthesis re-wired on the pico-second timescale. Link *Design of Four Small-Molecule-Inducible Systems in the Yeast Chromosome, Applied to Optimize Terpene Biosynthesis. Link A Genetic Programming Approach to Engineering MRI Reporter Genes. Metabolic Engineering. Antika T.R.

DNA 52

DNA Engineering RNA Science 52

Drug Target Review

DECEMBER 11, 2024

Discovering and optimising potent therapeutics that direct the immune response against these targets. This requires a deep understanding of how the key components of the immune system – antibodies and TCRs – recognise and interact with their targets on cancer cells. Nature Reviews Drug Discovery. Science Advances.

Immune Response 52

Immune Response Engineering Therapies Small Molecule 52